GDTC revenueFY2025SGD 324.4K
- FY YoY
- +366.7%
GDTC revenue was SGD 324.4K for fiscal 2025 (ended Dec 31, 2025), up 366.7% from fiscal 2024. It rose in 2 of the last 4 fiscal years. Fiscal 2025 is the highest of the 5 fiscal years on file.
CytoMed Therapeutics Limited (GDTC) financials
For fiscal 2025 (ended Dec 31, 2025), CytoMed Therapeutics Limited reported SGD 324.4K of revenue and -SGD 3.98M of net income. Figures are in SGD, the currency of its SEC filings.
- Revenue, FY2025
- SGD 324.4K
- Revenue growth, YoY
- +366.7%
- Net income, FY2025
- -SGD 3.98M
- Net margin
- -1227.1%
- Free cash flow, FY2025
- -SGD 4.34M
- EPS, diluted, FY2025
- -SGD 0.34
- Cash
- SGD 2.10M
- Total debt
- SGD 368.7K
FY2021FY2025
FY2020FY2025
FY2020FY2025
GDTC revenue and earnings growth
GDTC net incomeFY2025-SGD 3.98M
GDTC net income was -SGD 3.98M for fiscal 2025 (ended Dec 31, 2025), compared with -SGD 2.52M in fiscal 2024.
GDTC EPSFY2025-SGD 0.34
GDTC diluted EPS was -SGD 0.34 for fiscal 2025 (ended Dec 31, 2025), compared with -SGD 0.22 in fiscal 2024.
GDTC free cash flowFY2025-SGD 4.34M
GDTC free cash flow was -SGD 4.34M for fiscal 2025 (ended Dec 31, 2025), compared with -SGD 4.11M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | SGD 324.4K | SGD 69.5K | SGD 285.7K | SGD 2.1K | SGD 3.4K | - |
| Research and development | SGD 2.22M | SGD 1.91M | SGD 1.59M | SGD 1.52M | SGD 1.09M | SGD 1.04M |
| Interest expense | SGD 20.9K | SGD 20.3K | SGD 51.3K | SGD 125.2K | SGD 117.7K | SGD 105.5K |
| Pre-tax income | -SGD 4.00M | -SGD 2.52M | -SGD 4.13M | -SGD 3.13M | -SGD 2.05M | -SGD 1.94M |
| Income tax | - | - | SGD 653 | SGD 1.6K | - | - |
| Net income | -SGD 3.98M | -SGD 2.52M | -SGD 4.13M | -SGD 3.13M | -SGD 2.05M | -SGD 1.94M |
| EPS, basic | -SGD 0.34 | -SGD 0.22 | -SGD 0.39 | -SGD 0.40 | -SGD 0.30 | - |
| EPS, diluted | -SGD 0.34 | -SGD 0.22 | -SGD 0.39 | -SGD 0.40 | -SGD 0.30 | -SGD 0.33 |
| Diluted shares | 11.6M | 11.5M | 10.6M | 7.9M | 6.9M | 5.9M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | SGD 2.10M | SGD 4.70M | SGD 6.22M | SGD 1.58M | SGD 2.51M | SGD 885.3K |
| Receivables | SGD 1.57M | SGD 1.03M | SGD 1.10M | SGD 914.1K | SGD 769.0K | - |
| Current assets | SGD 3.66M | SGD 6.00M | SGD 10.10M | SGD 2.49M | SGD 3.28M | - |
| Goodwill | SGD 355 | SGD 355 | SGD 355 | SGD 355 | SGD 355 | - |
| Total assets | SGD 7.98M | SGD 10.07M | SGD 12.37M | SGD 5.23M | SGD 6.08M | - |
| Current liabilities | SGD 709.2K | SGD 606.6K | SGD 716.9K | SGD 4.17M | SGD 2.94M | - |
| Long-term debt | SGD 368.7K | SGD 394.3K | SGD 407.8K | SGD 468.8K | SGD 539.1K | - |
| Total debt | SGD 368.7K | SGD 394.3K | SGD 407.8K | SGD 468.8K | SGD 539.1K | - |
| Total liabilities | SGD 1.13M | SGD 1.02M | SGD 1.12M | SGD 4.64M | SGD 3.49M | - |
| Shareholders' equity | SGD 6.54M | SGD 8.97M | SGD 11.24M | SGD 586.3K | SGD 2.59M | SGD 475.8K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -SGD 3.70M | -SGD 2.71M | -SGD 3.53M | -SGD 1.40M | -SGD 1.71M | -SGD 849.4K |
| Capital expenditures | SGD 637.9K | SGD 1.40M | SGD 58.3K | SGD 473.8K | SGD 582.4K | SGD 244.7K |
| Free cash flow | -SGD 4.34M | -SGD 4.11M | -SGD 3.59M | -SGD 1.87M | -SGD 2.30M | -SGD 1.09M |
| Investing cash flow | SGD 929.3K | SGD 1.13M | -SGD 2.73M | -SGD 473.3K | -SGD 823.7K | -SGD 513.1K |
| Financing cash flow | SGD 208.6K | -SGD 64.9K | SGD 10.92M | SGD 968.7K | SGD 4.17M | SGD 1.88M |
| Stock-based compensation | SGD 694.2K | - | - | - | - | - |
| Depreciation and amortization | SGD 371.0K | SGD 322.2K | SGD 374.8K | SGD 379.7K | SGD 316.7K | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | 366.7% | -75.7% | 13525.1% | -37.8% | - | - |
| Net margin | -1227.1% | -3621.1% | -1446.5% | -149318.5% | -60897.9% | - |
| Free cash flow margin | -1336.5% | -5913.8% | -1256.3% | -89280.1% | -68131.2% | - |
| Return on equity | -60.8% | -28.1% | -36.8% | -534.1% | -79.2% | -406.8% |
| Return on assets | -49.8% | -25.0% | -33.4% | -59.9% | -33.7% | - |
| Current ratio | 5.17 | 9.89 | 14.08 | 0.60 | 1.12 | - |
| Debt to equity | 0.06 | 0.04 | 0.04 | 0.80 | 0.21 | - |
Source: XBRL data CytoMed Therapeutics Limited files with the SEC, latest filing dated Mar 31, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
GDTC peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| GDTC | SGD 324.4K | +366.7% | -SGD 3.98M | -1227.1% | $10.2M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
GDTC FAQ
8 questionsWhat is GDTC revenue?
CytoMed Therapeutics Limited (GDTC) reported SGD 324.4K of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 366.7% from the year before.Is GDTC profitable?
No. CytoMed Therapeutics Limited reported a net loss of SGD 3.98M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does GDTC have?
CytoMed Therapeutics Limited reported SGD 2.10M in cash and cash equivalents and SGD 368.7K of debt on its most recent balance sheet in SEC filings.How fast is GDTC revenue growing?
CytoMed Therapeutics Limited's revenue changed +366.7% in fiscal 2025, to SGD 324.4K.What is GDTC free cash flow?
CytoMed Therapeutics Limited generated -SGD 4.34M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -SGD 3.70M less capital expenditures.What is GDTC earnings per share?
Diluted earnings per share were -SGD 0.34 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did GDTC last report financial results?
The latest statements here come from CytoMed Therapeutics Limited's 20-F filed on Mar 31, 2026, covering the period ended Dec 31, 2025.Where does this GDTC financial data come from?
Quantisnow builds these statements from the structured XBRL data CytoMed Therapeutics Limited files with the SEC. It is provided for information only and is not investment advice.